Table 1.
Meningococcal conjugate and protein vaccines authorized for marketing and sale in Canada.
| Brand name | Current distributor | Composition: polysaccharide and carrier protein | Acronym used in manuscript | Authorization date |
|---|---|---|---|---|
| Menjugate™ | GlaxoSmithKline | C with CRM197 | MenC-Con (CRM) | September 2001 |
| Neisvac-C™ | Pfizer | C with TT | MenC-Con (TT) | January 2002 |
| Meningitec™ | Nuron Biotech | C with CRM197 | MenC-Con (CRM) | February 2004∗ |
| Menactra™ | Sanofi Pasteur | ACWY with DT | MenACWY-Con (DT) | October 2006 |
| Menveo™ | GlaxoSmithKline | ACWY with CRM197 | MenACWY-Con (CRM) | July 2010 |
| Nimenrix™ | Pfizer | ACWY with TT | MenACWY-Con (TT) | August 2013 |
| Bexsero™ | GlaxoSmithKline | NHBA, NadA, fHbp, and OMV (PorA P1.4) | Men-Prot or 4CMenB | December 2013 |
| Trumenba™ | Pfizer | Bivalent FHbp | Men-Prot or MenB-FHbp | July 2018 |
∗Withdrawn from marketing and authorization suspended in April 2014 following a problem with the production process.